The substitution of coagulation factors can achieve causal treatment.Â ATIII can be substituted in cases of inherited (prophylaxis and treatment of ongoing thrombosis) or acquired deficiency (increased consumption in DIC and sepsis). Fresh frozen plasma (FFP) contains the natural balance of procoagulant and anticoagulant factors.

Antithrombotic treatment decision should be based on a risk-benefit analysis.

Different anticoagulants and antiplatelets are available to prevent recurrent VTE.